Spots Global Cancer Trial Database for cancer vaccines
Every month we try and update this database with for cancer vaccines cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety Study of a Liposomal Vaccine to Treat Malignant Melanoma | NCT01052142 | Melanoma | Lipovaxin-MM | 18 Years - | Lipotek Pty Ltd | |
| Safety and Immunological Response Rate Study of THERATOPE® Vaccine in Metastatic Breast Cancer Patients | NCT00046371 | Breast Neoplasm... | THERATOPE® vacc... | 18 Years - | Oncothyreon Canada Inc. | |
| KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer | NCT06411691 | Colorectal Canc... Pancreatic Canc... | KRAS Vaccine wi... Balstilimab Botensilimab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma | NCT04248569 | Fibrolamellar H... | DNAJB1-PRKACA p... Nivolumab Ipilimumab | 12 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy | NCT03149003 | Glioblastoma | DSP-7888 Dosing... Bevacizumab | 18 Years - | Sumitomo Pharma America, Inc. | |
| Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer | NCT04799431 | Pancreatic Canc... Colorectal Canc... | Neoantigen Vacc... Retifanlimab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Lentivirus Transduced Acute Myeloid Leukaemia Blasts Expressing B7.1 (CD80) and IL-2 | NCT00718250 | Leukemia, Myelo... | RFUSIN2-AML1 Donor leukocyte... RFUSIN2-AML1 an... RFUSIN2-AML1 an... | 18 Years - | King's College Hospital NHS Trust | |
| DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma | NCT04248569 | Fibrolamellar H... | DNAJB1-PRKACA p... Nivolumab Ipilimumab | 12 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Safety Study of a Liposomal Vaccine to Treat Malignant Melanoma | NCT01052142 | Melanoma | Lipovaxin-MM | 18 Years - | Lipotek Pty Ltd | |
| A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy | NCT03149003 | Glioblastoma | DSP-7888 Dosing... Bevacizumab | 18 Years - | Sumitomo Pharma America, Inc. | |
| Safety and Immunological Response Rate Study of THERATOPE® Vaccine in Metastatic Breast Cancer Patients | NCT00046371 | Breast Neoplasm... | THERATOPE® vacc... | 18 Years - | Oncothyreon Canada Inc. | |
| Lentivirus Transduced Acute Myeloid Leukaemia Blasts Expressing B7.1 (CD80) and IL-2 | NCT00718250 | Leukemia, Myelo... | RFUSIN2-AML1 Donor leukocyte... RFUSIN2-AML1 an... RFUSIN2-AML1 an... | 18 Years - | King's College Hospital NHS Trust | |
| Novel Adjuvants for Peptide-Based Melanoma Vaccines | NCT00028431 | Melanoma | MDX-CTLA4 Antib... | 18 Years - | University of Southern California |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
